Rafferty Asset Management LLC Has $1.87 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Rafferty Asset Management LLC lowered its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 47.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,160 shares of the company's stock after selling 40,297 shares during the quarter. Rafferty Asset Management LLC owned 0.09% of Mirum Pharmaceuticals worth $1,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in MIRM. MPM Bioimpact LLC increased its position in Mirum Pharmaceuticals by 19.7% during the 4th quarter. MPM Bioimpact LLC now owns 589,579 shares of the company's stock valued at $24,379,000 after purchasing an additional 96,856 shares during the period. AlphaQuest LLC increased its position in Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares during the period. Golden State Equity Partners increased its position in Mirum Pharmaceuticals by 1,390.8% during the 4th quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock valued at $801,000 after purchasing an additional 18,080 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at approximately $277,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at approximately $413,000.

Mirum Pharmaceuticals Trading Down 0.1%

Shares of Mirum Pharmaceuticals stock traded down $0.05 on Friday, reaching $44.00. 164,520 shares of the company's stock were exchanged, compared to its average volume of 522,623. The company has a market capitalization of $2.18 billion, a P/E ratio of -21.78 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.83 and a 52 week high of $54.23. The firm's 50-day moving average is $42.95 and its two-hundred day moving average is $44.57. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. The firm had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.54) EPS. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 57,606 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the transaction, the senior vice president now directly owns 4,841 shares of the company's stock, valued at $214,698.35. This represents a 92.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Peter Radovich sold 7,879 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the transaction, the chief operating officer now directly owns 18,672 shares in the company, valued at $825,489.12. The trade was a 29.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 92,764 shares of company stock valued at $4,109,161 over the last ninety days. 14.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MIRM. JMP Securities increased their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research report on Friday, May 9th. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $73.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday. Finally, Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $60.73.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.